Participants were randomized using computer-generated random numbers into 2 groups. Group I included 32 women who received oxytocin infusion before placental delivery just after cord clamping and group II included 32 women who received oxytocin infusion after placental delivery. In both groups 10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Participants were randomized using computer-generated random numbers into 2 groups. Group I included 32 women who received oxytocin infusion before placental delivery just after cord clamping and group II included 32 women who received oxytocin infusion after placental delivery. In both groups 10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.

Inclusion Criteria:

• Age 18 - 40 years
• singleton full term pregnancy.
• Candidate for elective cesarean delivery under spinal anaesthesia

Exclusion Criteria:

• women at high risk for intraoperative bleeding as those with placenta previa or other placental abnormalities
• women with bleeding or coagulation disorders.
• Medical disorder associating pregnancy as preeclampsia or diabetes
• Allergy or contraindications to oxytocin
• Fetal macrosomia, or congenital anomalies
• Polyhydramnios
• Uterine abnormalities as fibroids
• Women with intraoperative complications as vascular or visceral injuries